NCT05764044 (AddChemo) is a Phase 3 clinical trial of cisplatin, gemcitabine in Cervical Cancer, sponsored by Hospital do Coracao.

Who is sponsoring NCT05764044?

NCT05764044 is sponsored by Hospital do Coracao.

What drugs are being tested in NCT05764044?

Interventions in NCT05764044: cisplatin, gemcitabine, Follow-up.

What condition does NCT05764044 study?

NCT05764044 studies Cervical Cancer, Cervix Cancer, Cervix Neoplasm.

Is NCT05764044 still recruiting?

NCT05764044 is currently recruiting now. Last updated 30 July 2024.

Last reviewed 2024-07-30 · How we verify

NCT05764044: AddChemo

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

Recruiting now Phase 3 Last updated 30 July 2024

What this trial tests

Phase 3 trial testing cisplatin, gemcitabine in Cervical Cancer in 365 participants. Currently enrolling.

Timeline

27 March 2024

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Hospital do Coracao
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	365
Start date	27 March 2024
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	26 locations across Brazil

Drugs / interventions tested

cisplatin, gemcitabine
Follow-up

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →
Cervix Cancer — all drugs for Cervix Cancer →
Cervix Neoplasm — all drugs for Cervix Neoplasm →

Sponsor

Hospital do Coracao

Who can join

Adults 18 to 70, female only, with Cervical Cancer or Cervix Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study hypothesizes that patients who persist with cell-free human papillomavirus deoxyribonucleic acid (cfHPV-DNA) plasma expression at the end of standard treatment, can derive the benefit of using adjuvant chemotherapy in locally advanced cervical cancer (CC). After standard treatment based on concomitant chemoradiotherapy regime, a qualitative and quantitative research of cfHPV-DNA in plasma of patients will be conducted. Patients who have positive research for plasma cfHPV-DNA at the end of chemoradiotherapy treatment will be randomized to receive two additional cycles of adjuvant chemotherapy or observation. Patients will be followed with conduction of computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Viral oncogenesis in cancer: from mechanisms to therapeutics.
Xiao Q, Liu Y, Li T, Wang C, et al · · 2025 · cited 45× · PMID 40350456 · DOI 10.1038/s41392-025-02197-9

Verify or expand the search:

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Hospital do Coracao trials

Trials by the same sponsor.

NCT07534163 — III Brazilian Registry of Heart Failure · not yet recruiting
NCT07129733 — Oral Care Layered Enhancement for Improved Oral Hygiene in Intensive Care Units · NA · not yet recruiting
NCT07037524 — Low Dose Radiotherapy for Heart Failure · Phase 1, PHASE2 · not yet recruiting
NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
NCT06547892 — Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05764044 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital do Coracao
Last refreshed: 30 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05764044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing